Journal of Hematology & Oncology

official impact factor 2.93
Search for
Advanced search
Journal of Hematology & Oncology
Tools
Share this article
Open Access Highly Access

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Guoqing Wei, Shamudheen Rafiyath and Delong Liu*

Journal of Hematology & Oncology 2010, 3:47 doi:10.1186/1756-8722-3-47

Accesses  

  • Last 30 days: 318 accesses
  • Last 365 days: 3890 accesses
  • All time: 7759 accesses

Cited by

BioMed Central: 3 citations

Review   Open Access Highly Accessed

Current management and novel agents for malignant melanoma

Byung Lee, Nikhil Mukhi, Delong Liu Journal of Hematology & Oncology 2012, 5:3 (14 February 2012)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Short report   Open Access

Development of a highly sensitive method for detection of JAK2V617F

Anna H Zhao, Rufei Gao, Zhizhuang J Zhao Journal of Hematology & Oncology 2011, 4:40 (10 October 2011)

Abstract | Full text | PDF | PubMed

Letter to the Editor   Open Access Highly Accessed

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Kazuma Ohyashiki Journal of Hematology & Oncology 2011, 4:32 (2 August 2011)

Abstract | Full text | PDF | PubMed

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations